In utero exposure to IBD drugs doesn’t up kids’ infection risk

Reuters Health - 28/10/2020 - Children exposed in utero to medications used to treat inflammatory bowel disease (IBD) are not at increased risk of antibiotic-treated infection or severe infection requiring hospitalization, according to new findings. Prenatal exposure to anti-tumor necrosis factor-alpha (anti-TNF-alpha) or thiopurines were also not associated with increased risk of adverse vaccine reactions, growth failure, autoimmune disease or malignancy, Dr. Shannon Linda Kanis of Erasmus Medical Center in Rotterdam, The Netherlands, and colleagues found. While the use of IBD drugs in pregnancy has not been linked to adverse pregnancy outcomes, the authors note in Gut, "the impact on the development of children's immune system, growth and risk of autoimmune diseases and malignancies later in life is poorly understood." To better understand long-term outcomes, they looked at 1,000 children born to 626 mothers with IBD in 1999-2019. Sixty-one percent of mothe...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 28 October, 20206 November, 2020